Bitcoin steigt nach dem Halving wieder über 9‘000 Franken. Jetzt Bitcoin handeln! -w-
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
06.04.2020 05:49:13

Gilead Has Treated More Than 1,700 COVID-19 Patients With Remdesivir

Gilead Sciences (NASDAQ: GILD) has made remdesivir, its Ebola-turned-COVID-19 drug, available to more than 1,700 patients through compassionate-use and expanded-access programs, according to an update from Gilead's chairman and CEO, Daniel O'Day, that was posted on the company's website on Saturday.The number of COVID-19 patients treated with remdesivir is likely to go higher. On Friday, EU regulators recommended expanding access to remdesivir for patients who are unable to partake in one of the nine clinical trials testing remdesivir that are ongoing or in the process of being set up.Because remdesivir isn't approved to treat any disease -- it was never approved to treat Ebola given the lackluster clinical trial results and the waning Ebola virus outbreak -- there wasn't a warehouse full of the drug nor a manufacturing plant set up for large-scale production.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

(Anzeige)Passende emittierte Barrier Reverse Convertibles

Basiswert Valor Fälligkeitstag Maximale Rendite p.a.
Gilead Sciences Inc. / Johnson & Johnson / Pfizer Inc. 39255387 05.08.2020 2.47 %